Montecito Bank & Trust Has $1.17 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Montecito Bank & Trust lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 89.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,114 shares of the biopharmaceutical company’s stock after purchasing an additional 526 shares during the quarter. Montecito Bank & Trust’s holdings in Regeneron Pharmaceuticals were worth $1,171,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of REGN. Graypoint LLC raised its stake in Regeneron Pharmaceuticals by 3.3% in the third quarter. Graypoint LLC now owns 2,346 shares of the biopharmaceutical company’s stock valued at $2,466,000 after buying an additional 76 shares during the period. Concurrent Investment Advisors LLC grew its position in Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 861 shares of the biopharmaceutical company’s stock worth $906,000 after acquiring an additional 30 shares during the last quarter. Umpqua Bank raised its stake in shares of Regeneron Pharmaceuticals by 2.3% during the third quarter. Umpqua Bank now owns 1,426 shares of the biopharmaceutical company’s stock valued at $1,499,000 after acquiring an additional 32 shares during the last quarter. Catalina Capital Group LLC raised its position in shares of Regeneron Pharmaceuticals by 13.6% during the third quarter. Catalina Capital Group LLC now owns 343 shares of the biopharmaceutical company’s stock worth $361,000 after acquiring an additional 41 shares during the last quarter. Finally, Crestwood Advisors Group LLC lifted its holdings in Regeneron Pharmaceuticals by 18.4% in the third quarter. Crestwood Advisors Group LLC now owns 476 shares of the biopharmaceutical company’s stock valued at $500,000 after buying an additional 74 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $816.65 on Thursday. The company has a 50 day moving average price of $1,035.92 and a 200-day moving average price of $1,038.36. The company has a market capitalization of $90.03 billion, a PE ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on REGN shares. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,092.62.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.